“Global Cardiac Resynchronization Therapy (CRT) Devices Market: Growth, Outlook, and Competitive Analysis, 2018 – 2030” is the most recent market study released by Credence Research, Inc. The global Cardiac Resynchronization Therapy (CRT) Devices market had a revenue of about USD 4.8 billion in 2022. It is predicted to increase at a CAGR of more than 4.50% from 2018 to 2030, reaching about USD 6.53 billion.
Cardiovascular disorders are treated using cardiac resynchronization therapy. CRT devices are those that are employed in cardiac resynchronization therapy. Arrhythmias, or irregular heartbeats, can be brought on by various factors, including aging, heart injury, genetics, and previously taken medications. Biventricular pacing, often known as CRT, treats heart failure patients with irregular heartbeats and lessens their symptoms. The CRT devices resynchronize the heart’s ventricular contractions in arrhythmic patients. The implantable devices known as the Global Cardiac Resynchronization Therapy (CRT) Market are made of a small titanium metal case, a microcontroller, and an encased battery. To transmit information signals from the heart to the device that transmits electrical impulses to the heart, insulated cables known as leads are implanted along with the device.
Rising alcohol consumption, smoking rates, and food preferences for unhealthy foods increase the market demand. As a result of all of these reasons, the number of patients will probably rise. The need for CRT device implants is rising along with the patient population. Also, there is a growing elderly population, which will raise the demand for CRT devices like defibrillators. Defibrillators are electrical generators that can revive patients whose hearts have stopped. CRT-Defibrillators can help prevent sudden cardiac death. Hence, as the elderly population grows, so does the demand for these defibrillators, and as people live longer, so does the market’s potential for expansion. The market demand is increasing since sudden cardiac death is more common in older individuals.
Browse the market research report covering the full company profiles, size, trends, strategies @ Cardiac Resynchronization Therapy (CRT) Devices Market
List of Top Companies Operating in the Cardiac Resynchronization Therapy (CRT) Devices Market
- Medtronic Plc
Medtronic Plc develops, produces, distributes, and sells therapies and services that rely on medical devices. Heart and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group, and Diabetes Group are its functional divisions. The Cardiac and Vascular Group segment comprises the divisions for Coronary and Structural Heart, Aortic and Peripheral Vascular, and Cardiac Rhythm and Heart Failure. Surgical Innovations and the Respiratory, Gastrointestinal, and Renal divisions form the Minimally Invasive Technologies Group segment. Spine, Brain, Specialized Therapies, and Pain Therapies are divisions of the Restorative Therapies Group. The discovery, production, and marketing of goods and services for the control of Type I and Type II diabetes are the primary objectives of the Diabetes Group segment. Dublin, Ireland, serves as the company’s headquarters. It was established in 1949.
Abbott Laboratories researches, develops, produces, and markets a vast and varied range of medical products. It works through the following divisions: Established Pharmaceutical Products; Nutritional; Diagnostic; Cardiovascular and Neuromodulation; and Others. The foreign sales of branded generic pharmaceutical products are included in the Established Pharmaceutical Products section. The Nutritional Products section services the global sales of nutritious items for adults and children. The segment for Diagnostic Products sells diagnostic tools and procedures to blood banks, medical facilities, private labs, and other testing locations. The segment for vascular products covers the market for coronary, endovascular, structural heart, vessel closure, and other medical device products. The Abbott Medical Optics section is included. Abbott acquired Walk Vascular, LLC, a medical device firm specializing in barely perceptible mechanical target thrombectomy frameworks, in September 2021. Abbott was founded by Wallace Calvin Abbott in 1888 and had its headquarters in Abbott Park, Illinois. This acquisition expanded the organization’s line of endovascular products.
- Boston Scientific Corporation.
Boston Scientific Corp. develops, produces, and markets medical devices in interventional medical specialties. The Rhythm and Brain, Cardiovascular, and MedSurg parts comprise how it functions. The sector of Rhythm and Neuro creates implanted devices that track the heartbeat and give electricity to treat cardiac problems. The cardiovascular category comprises technologies for structural heart diseases and technology for diagnosing and treating cardiovascular disorders like coronary artery disease. The MedSurg sector is centered on Endoscopy, which offers tools to diagnose and treat a wide range of gastrointestinal and pulmonary problems using cutting-edge and invasive technologies. Boston Scientific, BIOTRONIK, and Abbott Laboratories released new CRT devices in 2017, the Resonate CRT-D and the EDORA quadripolar CRT-P. The company was formed by John E. Abele and Pete Michael Nicholas on June 29, 1979, and has its corporate headquarters in Marlborough, Massachusetts. So, these goods support companies in solidifying their places in the lucrative CRT devices market.
- Biotronik SE & Co., KG.
BIOTRONIK is a privately held company that offers goods and services that prolong and enhance the lives of people with endovascular and cardiovascular disorders. We have put patient care first for 60 years, and we still do. Pacemakers, stents, implantable defibrillators, and remote monitoring services are just a few of the innovative, secure, and dependable devices the company provides to patients in more than 100 countries. In May 2020, Biotronik, Inc. partnered with Acutus Medical to provide a broad range of catheter-based cardiovascular arrhythmia therapy items, such as electrophysiology, planning, and removal, across a few niche markets, including Europe and Asia. The organization’s portfolio was increased, and the development approach was improved.
- MicroPort Scientific Corporation
MicroPort is a global manufacturer of medical devices built on the principle that everyone has the right to receive high-quality medical care and to live healthier, longer lives. All of our solutions are geared to support this conviction. Our close partnership with physicians and medical societies enables us to expedite innovation and develop medical treatment-transforming solutions. MicroPort operates in various foreign areas, including orthopedics, cardiovascular intervention, cardiac rhythm management, electrophysiology, endovascular, and peripheral vascular intervention. In October 2021, MicroPort acquired Hemovent GmbH, a German ECLS company, for USD 138.71 million. This investment aided in its expansion in Germany.
- Livanova, plc.
LivaNova is a global medical technology firm with decades of expertise and an unwavering dedication to patients. The company’s products and therapies for the head and heart are geared toward improving lives. Innovation in health care is what genuinely matters. Its products and treatments are utilized globally. Having a presence in over 100 countries, their team of around 3,000 skilled individuals works to enhance and maintain the quality of life for patients.
- Medico S.p.A.
Medico S.p.A. was founded in 1973 and remained a privately held, autonomous organization. They have been conducting cardiac stimulation for over 45 years to provide doctors and patients with high technical assurance. Since the 1980s, when Medico introduced single-lead VDD pacing with a 3 cm atrial floating dipole, the company’s pioneering spirit in advancing new technologies has been on full display. Trans Valvular Impedance (TVI) is an impedance signal generated within the right atrium and ventricle using standard pacing electrodes. Its measurement has been a major focus for the company in recent years. This signal has the potential to reveal crucial details about the heart’s mechanical health. In particular, preload and stroke changes in volume can be identified to track hemodynamic stability over time.
All pacemakers in the Sophs and Helios families feature this cutting-edge system, which provides real-time data on device programming and drug therapy efficacy. Ejection checking following ventricular pacing (using methods for automatic adjustment of pacing energy) and noticing are two other examples of TVI-based applications. (safety pacing is delivered if ventricular oversensing is suspected).
- Lepu Medical Technology (Beijing) Co., Ltd.
Established in 1999, Lepu Medical Technology (Beijing) Co., Ltd. Lepu Medical is an industry leader in cutting-edge medical technology design, production, and distribution. Lepu Medical is now a world-renowned leader in a wide range of medical specialties, including cardiovascular procedures, structural heart diseases, neuro intervention, anesthesia, cardiac rhythm management, and critical care, in vitro diagnostics, electrocardiogram (ECG) and patient monitoring; hemodialysis; orthopedics; dermatology; and general surgery.